Voyager Therapeutics (VYGR) Cash from Investing Activities (2014 - 2026)

Voyager Therapeutics has disclosed Cash from Investing Activities across 13 years of filings, most recently posting $8.1 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $8.1 million, down 80.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $92.3 million (up 117.76% YoY), and the FY2025 annual result was $125.4 million, up 232.24% from the prior year.
• Cash from Investing Activities came in at $8.1 million for Q1 2026 at Voyager Therapeutics, down from $47.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $64.4 million in Q3 2024 to a low of -$158.3 million in Q3 2023.
• The 5-year median for Cash from Investing Activities is $8.1 million (2026), against an average of -$6.5 million.
• Across the five-year window, Cash from Investing Activities soared 357.45% in 2022 and tumbled 762.93% in 2024, its largest moves.
• Voyager Therapeutics' Cash from Investing Activities stood at $14.1 million in 2022, then surged by 90.75% to $26.8 million in 2023, then slumped by 201.38% to -$27.2 million in 2024, then jumped by 274.33% to $47.4 million in 2025, then slumped by 82.92% to $8.1 million in 2026.
• The last three Cash from Investing Activities figures came in at $8.1 million (Q1 2026), $47.4 million (Q4 2025), and $34.9 million (Q3 2025), per Business Quant data.